Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation.

scientific article published on 23 November 2015

Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S40258-015-0204-3
P932PMC publication ID4740570
P698PubMed publication ID26597111

P50authorJörgen MöllerQ79193157
P2093author name stringAtaru Igarashi
Rei Goto
Reiko Yoshikawa
Alexandra J Ward
Kiyomi Suwa
P2860cites workLong-term prognosis of patients with acute myocardial infarction in the era of acute revascularization (from the Heart Institute of Japan Acute Myocardial Infarction [HIJAMI] registry).Q51049258
A catalogue of EQ-5D utility weights for chronic diseases among noninstitutionalized community residents in Korea.Q53069448
Web-based survey on smoking cessation behaviors of current and former smokers in Japan.Q53147568
International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?Q57227507
The effect of bronchitis, smoking, and occupation on ventilationQ76455131
Systematic review: smoking cessation intervention strategies for adults and adults in special populationsQ33256456
A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.Q33858665
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trialQ33897433
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trialQ33997418
Adult mortality attributable to preventable risk factors for non-communicable diseases and injuries in Japan: a comparative risk assessmentQ34145606
COPD in Japan: the Nippon COPD Epidemiology studyQ34553639
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.Q35537270
Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country SurveyQ36405951
Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation.Q36494908
Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialQ36941156
Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sampleQ37268243
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.Q38405712
Predictors of lapse and relapse to smoking in successful quitters in a varenicline post hoc analysis in Japanese smokersQ38430668
Medical care for chronic-phase stroke in JapanQ39626450
Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama studyQ39659131
Cost-utility analysis of varenicline, an oral smoking-cessation drug, in JapanQ39988937
Development of a screening questionnaire for tobacco/nicotine dependence according to ICD-10, DSM-III-R, and DSM-IV.Q40812875
Smoking cessation patterns and predictors of quitting smoking among the Japanese general population: a 1-year follow-up studyQ43240449
Smoking cessation treatment and outcomes patterns simulation: a new framework for evaluating the potential health and economic impact of smoking cessation interventionsQ43781923
Late relapse/sustained abstinence among former smokers: a longitudinal studyQ45147754
Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) projectQ46153737
Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trialQ46241957
Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokersQ50085911
P275copyright licenseCreative Commons Attribution-NonCommercial 4.0 InternationalQ34179348
P6216copyright statuscopyrightedQ50423863
P433issue1
P304page(s)77-87
P577publication date2016-02-01
P1433published inApplied Health Economics and Health PolicyQ15764758
P1476titleCost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation
P478volume14

Reverse relations

cites work (P2860)
Q58765273Application of discrete event simulation in health care: a systematic review
Q64111168Clinical Efficacy of Telemedicine Compared to Face-to-Face Clinic Visits for Smoking Cessation: Multicenter Open-Label Randomized Controlled Noninferiority Trial
Q60931942Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer
Q91761819Comparing Telemedicine and Face-to-Face Consultation Based on the Standard Smoking Cessation Program for Nicotine Dependence: Protocol for a Randomized Controlled Trial
Q38689880Examining the association of smoking with work productivity and associated costs in Japan.